Informative noncompliance in endpoint trials
نویسندگان
چکیده
Noncompliance with study medications is an important issue in the design of endpoint clinical trials. Including noncompliant patient data in an intention-to-treat analysis could seriously decrease study power. Standard methods for calculating sample size account for noncompliance, but all assume that noncompliance is noninformative, i.e., that the risk of discontinuation is independent of the risk of experiencing a study endpoint. Using data from several published clinical trials (OPTIMAAL, LIFE, RENAAL, SOLVD-Prevention and SOLVD-Treatment), we demonstrate that this assumption is often untrue, and we discuss the effect of informative noncompliance on power and sample size.
منابع مشابه
Frequentist Operating Characteristics of Bayesian Posterior Probability Designs for Medical Device Trials That Include a Single, Late-Information-Time, Interim Analysis
In medical device trials, a single, late-information-time interim analysis can substantially reduce time to regulatory filing. Moreover, candidate control devices are often the subject of their own recent regulatory study, if not of multiple studies. Entirely ignoring this information at the time of analysis is increasingly difficult to justify. In this paper, Bayesian posterior probability des...
متن کاملClinical Trials Simulation System
A generic template for clinical trials simulations that are typically required by statisticians is developed. Realistic clinical trials data sets are created using a unifying model that allows general correlation structures for endpoint*timepoint data and nonnormal distributions (including time-to-event), and computationally efficient algorithms are presented. The model allows for patient dropo...
متن کاملStatistical issues in randomized trials of cancer screening
BACKGROUND The evaluation of randomized trials for cancer screening involves special statistical considerations not found in therapeutic trials. Although some of these issues have been discussed previously, we present important recent and new methodologies. METHODS Our emphasis is on simple approaches. RESULTS We make the following recommendations: (1) Use death from cancer as the primary e...
متن کاملDesigning exploratory cancer trials using change in tumour size as primary endpoint.
In phase III cancer clinical trials, overall survival is commonly used as the definitive endpoint. In phase II clinical trials, however, more immediate endpoints such as incidence of complete or partial response within 1 or 2 months or progression-free survival (PFS) are generally used. Because of the limited ability to detect change in overall survival with response, the inherent variability o...
متن کاملClinical Trials Simulation: A Publicly Available, Grid-Enabled, GUI-Driven SAS System
A clinical trials system developed for Vertex Pharmaceuticals has become publically available on the Biopharmaceutical Network http://www.biopharmnet.com/innovation/trial_simulation/cts1.php. The system is a SAS/AF® based interface in which clinical trials’ simulation parameters can be entered; it can operate either on a SAS grid or as a stand-alone process. The statistical details are publishe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Current Controlled Trials in Cardiovascular Medicine
دوره 5 شماره
صفحات -
تاریخ انتشار 2004